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Dr Gus J. Vlahakes (Boston, Mass). First, I want to thank the
authors for providing the manuscript of the article and the presen-
tation well in advance of this meeting and also the Association for184 The Journal of Thoracic and Cardiovascular Surgthe privilege of discussing this. Second, I have no disclosures to re-
veal pertinent to this discussion.
Dr Paone, you and your coauthors have examined an important
subject of current interest that has been the subject of several stud-
ies in the last decade, the important ones being quoted in your
written article. With theMichigan Society of Thoracic and Cardio-
vascular Surgeons database, you have analyzed data from more
than 30,000 patients, and the power of this study rests in the large
number of patients derived from an audited, well-designed cardiac
surgical database. This foundation lends tremendous statistical
power and for all practical purposes eliminates the risk of type II
statistical errors.
The study confirms that after risk adjustment, red blood cell
transfusion remains a significant risk factor for complications
and mortality. The potential weakness of this study, however, as
you yourselves have pointed out, is the fact that the database
may not necessarily contain the data critical for analyzing transfu-
sion decisions, and in particular transfusion timing, relative to the
occurrence of complications, which themselves may mandate
transfusion.
As with previous studies on this subject, several important ques-
tions arise. Looking across the participating institutions, including
your own, do you have any preliminary analysis of transfusion trig-
gers for any institutions with fixed criteria such as hematocrit? If
so, were guidelines tailored to age, preoperative risk profile, or
other parameters? Importantly, can you determine from the data-
base or from participating institutions whether transfusions oc-
curred because of complications, as opposed to transfusion
before morbidity occurred? This question is based on your obser-
vation that the incidence of transfusion increased across the risk
strata that were studied. Previous studies have suggested that the
increment in risk produced by transfusion is proportional to the
number of units transfused. Are you able to confirm this from
your data?
Did you consider preoperative anemia as a factor leading to
transfusion, particularly in patients requiring more extensive pre-
operative evaluation and treatment? This question is suggested
by your observation that myocardial infarction within a week
of operation resulted in a higher incidence of transfusion, poten-
tially related to blood testing and care of the patient before
operation.
Previous studies have focused on 2 pathophysiologic mecha-
nisms to explain morbidity and mortality associated with transfu-
sions in the setting of cardiac surgery. One potential mechanism is
impaired oxygen transport with potential cardiac, neurologic, or
renal ischemia. The second purported mechanism is an increased
risk of infection, presumably as a result of immune response im-
pairment. Confirming that excess morbidity and mortality were
due to these mechanisms would further validate your findings.
Finally, some of these critical issues may be settled by the RE-
CESS trial currently in progress. This trial will test the hypothesis
that the risk of transfusion is related to the storage time of trans-
fused red blood cells.
Dr Paone. Thank you for your questions and your comments,
Dr Vlahakes. I will try to go through these one at a time.
With regard to your first point, we have asked a number of our
centers to provide the criteria that they use as transfusion triggers.
As you might expect, there is great variation in transfusionery c January 2012
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Mtriggers both during bypass and after the operation. We expected
to find that with a lower intraoperative transfusion trigger, at least
during bypass, those patients would be less likely to be transfused
in the operating room, and we did indeed find that. In addition, as
we looked at the incidence of transfusion postoperatively in these
patients, we expected that they would have a somewhat higher
rate, and they did. We also found that institutions that were
more likely to transfuse intraoperatively were also more likely
to transfuse postoperatively. So it is not all related to the trigger.
I think a lot of it has to do with your approach to blood transfu-
sion in general.
With regard to comparing transfusion rates and morbidities, we
did find—at least preliminarily, and we have not concluded the
analysis—that as you might also expect, as the risk level increases,
so does the risk of each of the major postoperative comorbidities.
Progressing from the less than 2% category to the 2% to 5% group
and so on, the rate of stroke increased, the rate of wound infection
increased, and so did rates of renal failure and the like. Again, we
are in the process of looking more closely at these data.
As we did mention in the article and at the end of our presenta-
tion here, we don’t have information yet on the volume of transfu-
sion. Again, it is a very large database, and so there are a lot of
things that we can and indeed plan to look at. A very preliminary
look at volumes of transfusion again confirms what you might ex-
pect from what we already know through the literature, which is
that as you increase the number of units of blood transfused to
each patient, their outcomes worsen. With respect to whether
this is related to the blood transfusion itself or is related to the co-
morbidities and the predicted risk, that analysis has not been fully
completed, and we will continue to look at this issue.
The role of anemia is questionable. Many articles that have
looked at these outcomes with regard to anemia or low hemato-
crits, particularly during bypass, have also shown relationships
with mortality and transfusion rate as well. One of the criticisms
of many of these studies looking at the role of hemodilutional ane-
mia in the operating room, particularly as it relates to the worsen-
ing outcomes, is that often the analyses do not include whether the
patients were transfused as well, and if so how much blood they
received. If you look at the demographic variables for patients
who get to lower levels of anemia, they tend to be the same exact
variables that predict transfusion. So it has been difficult at best to
try to discern whether it is actually the level of anemia that is caus-
ing the problem or the subsequent role of transfusion.
The mechanisms for how transfusion causes these outcomes, if
indeed it does, have been widely speculated on, including those
that you mentioned, immunosuppression, infection, and blood
storage time and duration. Again, those are issues that with the
size of the database we intend to try and look at to the best of
our ability in the future.
Dr Lokeswara Rao Sajja (Hyderabad, India). I congratulate
Dr Paone and colleagues on a nice presentation of a retrospective
analysis. There is enough evidence that the CABG performed with
off-pump technique has been associated with fewer homologous
blood transfusions. In this analysis, was the technique of off-
pump surgery applied in a comparable number of patients betweenThe Journal of Thoracic and Cathe 2 groups, those who received blood transfusion and those who
did not receive blood transfusion?
Dr Paone. These 31,818 patients were the total population of
patients undergoing CABG, including both on- and off-pump pro-
cedures. We did actually look briefly at the 2 groups. In the state of
Michigan, a little more than 9% of patients underwent off-pump
surgery. The transfusion rate in those cases was less than the trans-
fusion rate for the on-pump procedures, 41% versus about 57%. In-
terestingly, though, the mortality was about the same. The overall
mortalities were 2.2% in the off-pump cases and 2.1% in the on-
pump cases.
We then did the analysis that we showed for the entire group for
both groups separately. Although the strength of the relationship
was just slightly less for the off-pump cases, the relationship itself
held. When we adjusted for the predicted risk stratum, there was
still a significant relationship between transfusion itself—indepen-
dent of risk—and mortality in the off-pump cohort.
Dr Andrew C. Chang (Ann Arbor, Mich). Dr Paone, this study
and its analysis demonstrate the strength of a collaborative effort in
evaluating an important issue that crosses subspecialties in tho-
racic surgery. In the analysis, even though multivariate analysis
identified some important factors, has your group looked at the sig-
nificance of each of these factors with parsimonious model testing,
such as the Akaike information criterion, to determine the good-
ness of fit of the final model; that is, whether the use of transfusion
was as important as other comorbidities that are considered part of
the PROM score?
Dr Paone. We did not. We did the propensity score analysis,
and we subsequently did a standard multivariable analysis. Blood
transfusion again was an independent predictor, but that was the
extent of what we did.
Dr Michael Poullis (Liverpool, UK).We have repeated the ex-
act same study you have done in a single institution with 5500 pa-
tients and found exactly the same results as you have. The one
surprise finding, if you look at people who were discharged
home alive, their survival was not affected by blood transfusion,
which is a bit contrary to the literature. Have you looked at survival
and the effect of transfusion?
Dr Paone. Thank you for your question. No, we have not. We
have done some preliminary work that shows that at the lowest
risk level getting small amounts of transfusion does not seem to af-
fect survival. As I said, with the size of the database, we intend to
look at that a lot more deeply and to try and determine how we can
tease that out. This has been the question in this area for many
years. It has been clear that there is a relationship between mortal-
ity and transfusion. It has also been clear when you look at the data
that the patients who get transfusions tend to be sicker. And that is
what we have tried to sort out here. I think we have sorted it out
a bit, but clearly, more work needs to be done.
Dr Poullis. Yes, because I find it a little bit odd that the hazard
ratio of dying with transfusion is so high—you found 4, Murphy
found 6, we have 10 in Liverpool—and then as soon as you get dis-
charged home, it goes down to 1. It is probably the hosts more than
the blood. Of course, blood is bad, but I think it’s the hosts more
than the blood.rdiovascular Surgery c Volume 143, Number 1 185
